Clinical Trial Update: Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) [Phase 2]

View source ↗

Summary

Pilot Phase 2 study evaluating bevacizumab for dyspnea in post-acute sequelae of SARS-CoV-2 infection (long COVID); the trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Dyspnea Caused by 2019-nCoV | Phase 2 | Status: NOT_YET_RECRUITING